REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

29/04/2022 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc9454Ja&default-theme=true

RNS Number : 9454J  AstraZeneca PLC  29 April 2022

29 April 2022 17:30 BST

 

Results of Annual General Meeting held on 29 April 2022

 

AstraZeneca PLC announced the results of the voting at its Annual General
Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were
decided by poll vote. Resolutions 9 - 12 were passed as special resolutions;
all other resolutions were passed as ordinary resolutions.

 

     Resolution                                                                   Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 1   To receive the Company's Accounts, the Reports of the Directors and Auditor  1,203,570,226  99.85            1,828,274      0.15             1,205,398,500        77.79                                            5,547,341
     and the Strategic Report for the year ended 31 December 2021
 2   To confirm dividends                                                         1,193,597,088  98.93            12,920,907     1.07             1,206,517,995        77.87                                            4,366,330
 3   To reappoint PricewaterhouseCoopers LLP as Auditor                           1,198,088,929  99.29            8,509,251      0.71             1,206,598,180        77.87                                            4,347,248
 4   To authorise the Directors to agree the remuneration of the Auditor          1,204,954,300  99.87            1,563,462      0.13             1,206,517,762        77.87                                            4,311,513
 5a  To re-elect Leif Johansson as a Director                                     1,166,282,927  96.68            40,088,832     3.32             1,206,371,759        77.86                                            4,573,789
 5b  To re-elect Pascal Soriot as a Director                                      1,205,673,389  99.93            863,219        0.07             1,206,536,608        77.87                                            4,408,995
 5c  To elect Aradhana Sarin as a Director                                        1,204,771,723  99.86            1,661,294      0.14             1,206,433,017        77.86                                            4,512,437
 5d  To re-elect Philip Broadley as a Director                                    1,191,418,997  98.75            15,054,946     1.25             1,206,473,943        77.86                                            4,471,514
 5e  To re-elect Euan Ashley as a Director                                        1,205,615,431  99.93            843,877        0.07             1,206,459,308        77.86                                            4,486,117
 5f  To re-elect Michel Demaré as a Director                                      1,159,460,793  96.34            44,030,272     3.66             1,203,491,065        77.67                                            7,453,982
 5g  To re-elect Deborah DiSanzo as a Director                                    1,199,445,587  99.98            245,001        0.02             1,199,690,588        77.43                                            11,254,771
 5h  To re-elect Diana Layfield as a Director                                     1,206,239,742  99.98            251,612        0.02             1,206,491,354        77.87                                            4,454,103
 5i  To re-elect Sheri McCoy as a Director                                        1,199,985,750  99.46            6,515,562      0.54             1,206,501,312        77.87                                            4,444,145
 5j  To re-elect Tony Mok as a Director                                           1,205,526,446  99.92            961,584        0.08             1,206,488,030        77.86                                            4,457,427
 5k  To re-elect Nazneen Rahman as a Director                                     1,192,803,495  98.87            13,681,523     1.13             1,206,485,018        77.86                                            4,460,509
 5l  To elect Andreas Rummelt as a Director                                       1,205,642,938  99.93            816,947        0.07             1,206,459,885        77.86                                            4,485,572
 5m  To re-elect Marcus Wallenberg as a Director                                  979,070,782    81.15            227,477,101    18.85            1,206,547,883        77.87                                            4,397,534
 6   To approve the Annual Report on Remuneration for the year ended 31 December  1,109,853,237  92.23            93,486,120     7.77             1,203,339,357        77.66                                            7,606,290
     2021
 7   To authorise limited political donations                                     1,176,840,533  97.53            29,853,717     2.47             1,206,694,250        77.88                                            4,261,968
 8   To authorise the Directors to allot shares                                   1,112,092,040  92.70            87,623,060     7.30             1,199,715,100        77.43                                            11,230,323
 9   To authorise the Directors to disapply pre-emption rights                    1,193,005,130  99.11            10,731,935     0.89             1,203,737,065        77.69                                            7,206,669
 10  To authorise the Directors to further disapply pre-emption rights for        1,175,775,085  97.67            27,999,631     2.33             1,203,774,716        77.69                                            7,088,425
     acquisitions and specified capital investments
 11  To authorise the Company to purchase its own shares                          1,195,870,775  99.15            10,230,544     0.85             1,206,101,319        77.84                                            4,843,802
 12  To reduce the notice period for general meetings                             1,062,882,097  88.11            143,446,819    11.89            1,206,328,916        77.85                                            4,616,168
 13  To extend the AstraZeneca PLC 2012 Savings Related Share Option Scheme       1,200,174,255  99.53            5,676,533      0.47             1,205,850,788        77.82                                            5,094,639

 

A copy of the resolutions passed at the AGM (other than resolutions concerning
ordinary business) has been submitted to the National Storage Mechanism for
publication, and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Issued capital

As at 27 April 2022, the number of issued shares of the Company was
1,549,464,013 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all of the resolutions at the
AGM. In accordance with the Company's Articles of Association, on a poll every
member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPPUQUCUPPGQB